Does Axovant Have Any Hope in Alzheimer’s?

12:45 EDT 22 Sep 2016 | Science

Hey, remember Axovant? That’s the company that acquired a shelved Alzheimer’s candidate from GSK (intepirdine) and promptly went public in June of 2015 at what seemed a ridiculous valuation ($15/share, raising $315 million). People certainly made money on it, but jeez, the whole business really had a nasty look to it. The company’s stock hit $29 its

Original Article: Does Axovant Have Any Hope in Alzheimer’s?


More From BioPortfolio on "Does Axovant Have Any Hope in Alzheimer’s?"

Quick Search

Relevant Topic

GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...